-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 3, the official website of the State Administration of Food and Drug Administration showed that Qilu Pharmaceutical (Hainan) imatinib mesylate tablets were approved for production of imatinib mesylate tablets in 4 categories, which were deemed to have been reviewed and became the fourth domestic manufacturer.
June 3, 2021 Drug approval certificate pending information release
Data show that imatinib mesylate is a Bcr-Abl tyrosine kinase inhibitor developed by Novartis for the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumor (GIST) and other malignant tumors .
Sales of imatinib tablets in Chinese public medical institutions and physical pharmacies in cities in China
Source: Mi Nei Net Database
According to data from Minai.
Source: Meinenet MED2.
Prior to this, there were 4 manufacturers of imatinib mesylate tablets, and three domestic pharmaceutical companies of CSPC Ouyi Pharmaceutical, Jiangsu Haosen Pharmaceutical, and Shenzhen Xinlitai Pharmaceutical had all reviewed them.
Source: official website of the State Food and Drug Administration, Mi Nei.
